Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson's disease.

Yu RL, Tan CH, Lu YC, Wu RM.

Sci Rep. 2016 Jul 25;6:30424. doi: 10.1038/srep30424.

2.

Structural Imaging and Parkinson's Disease: Moving Toward Quantitative Markers of Disease Progression.

Sterling NW, Lewis MM, Du G, Huang X.

J Parkinsons Dis. 2016 May 27;6(3):557-67. doi: 10.3233/JPD-160824.

3.

Exercise for Individuals with Lewy Body Dementia: A Systematic Review.

Inskip M, Mavros Y, Sachdev PS, Fiatarone Singh MA.

PLoS One. 2016 Jun 3;11(6):e0156520. doi: 10.1371/journal.pone.0156520. eCollection 2016.

4.

Visual Hallucinations and Amyloid Deposition in Parkinson's Disease Dementia: A Case Report.

Um YH, Kim TW, Jeong JH, Seo HJ, Han JH, Hong SC, Jung WS, Choi WH, Lee CU, Lim HK.

Psychiatry Investig. 2016 May;13(3):364-9. doi: 10.4306/pi.2016.13.3.364. Epub 2016 May 18.

5.

The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease.

Collins LM, Williams-Gray CH.

Front Psychiatry. 2016 May 20;7:89. doi: 10.3389/fpsyt.2016.00089. eCollection 2016. Review.

6.

Quantitative EEG and Cognitive Decline in Parkinson's Disease.

Cozac VV, Gschwandtner U, Hatz F, Hardmeier M, Rüegg S, Fuhr P.

Parkinsons Dis. 2016;2016:9060649. doi: 10.1155/2016/9060649. Epub 2016 Apr 11. Review.

7.
8.

Converging mediators from immune and trophic pathways to identify Parkinson disease dementia.

Lue LF, Schmitz CT, Snyder NL, Chen K, Walker DG, Davis KJ, Belden C, Caviness JN, Driver-Dunckley E, Adler CH, Sabbagh MN, Shill HA.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 27;3(1):e193. doi: 10.1212/NXI.0000000000000193. eCollection 2016 Feb.

9.

Altered Expression Patterns of Inflammation-Associated and Trophic Molecules in Substantia Nigra and Striatum Brain Samples from Parkinson's Disease, Incidental Lewy Body Disease and Normal Control Cases.

Walker DG, Lue LF, Serrano G, Adler CH, Caviness JN, Sue LI, Beach TG.

Front Neurosci. 2016 Jan 14;9:507. doi: 10.3389/fnins.2015.00507. eCollection 2015.

10.

Lack of association between IL-10 and IL-18 gene promoter polymorphisms and Parkinson's disease with cognitive impairment in a Chinese population.

Liu Z, Guo J, Wang Y, Li K, Kang J, Wei Y, Sun Q, Xu Q, Xu C, Yan X, Tang B.

Sci Rep. 2016 Feb 2;6:19021. doi: 10.1038/srep19021.

11.

Memory for gist and detail information in patients with Parkinson's disease.

Yu RL, Tan CH, Wu YR, Wu RM, Chiu MJ, Hua MS.

BMJ Open. 2015 Nov 20;5(11):e009795. doi: 10.1136/bmjopen-2015-009795.

12.

The Progressive BSSG Rat Model of Parkinson's: Recapitulating Multiple Key Features of the Human Disease.

Van Kampen JM, Baranowski DC, Robertson HA, Shaw CA, Kay DG.

PLoS One. 2015 Oct 6;10(10):e0139694. doi: 10.1371/journal.pone.0139694. eCollection 2015.

13.

Clinical and Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with Lewy Bodies.

Petrova M, Mehrabian-Spasova S, Aarsland D, Raycheva M, Traykov L.

Dement Geriatr Cogn Dis Extra. 2015 May 29;5(2):212-20. doi: 10.1159/000375363. eCollection 2015 May-Aug.

14.

Cognitive reserve and β-amyloid pathology in Parkinson disease.

Lucero C, Campbell MC, Flores H, Maiti B, Perlmutter JS, Foster ER.

Parkinsonism Relat Disord. 2015 Aug;21(8):899-904. doi: 10.1016/j.parkreldis.2015.05.020. Epub 2015 May 27.

15.

Comprehensive treatment of dementia with Lewy bodies.

Boot BP.

Alzheimers Res Ther. 2015 May 29;7(1):45. doi: 10.1186/s13195-015-0128-z. eCollection 2015.

16.

Gout and the risk of dementia: a nationwide population-based cohort study.

Hong JY, Lan TY, Tang GJ, Tang CH, Chen TJ, Lin HY.

Arthritis Res Ther. 2015 May 28;17:139. doi: 10.1186/s13075-015-0642-1.

17.

Prevalence and risk factors of cognitive impairment in Parkinson disease: a population-based case-control study in Taiwan.

Huang YC, Wu ST, Lin JJ, Lin CC, Kao CH.

Medicine (Baltimore). 2015 May;94(17):e782. doi: 10.1097/MD.0000000000000782.

18.

Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson's disease.

Sandoval-Rincón M, Sáenz-Farret M, Miguel-Puga A, Micheli F, Arias-Carrión O.

Front Neurol. 2015 Mar 31;6:71. doi: 10.3389/fneur.2015.00071. eCollection 2015. Review.

19.

Impact of aerobic exercise on neurobehavioral outcomes.

Smith PJ, Potter GG, McLaren ME, Blumenthal JA.

Ment Health Phys Act. 2013 Oct;6(3):139-153.

20.

Virtual multiple errands test (VMET): a virtual reality-based tool to detect early executive functions deficit in Parkinson's disease.

Cipresso P, Albani G, Serino S, Pedroli E, Pallavicini F, Mauro A, Riva G.

Front Behav Neurosci. 2014 Dec 5;8:405. doi: 10.3389/fnbeh.2014.00405. eCollection 2014.

Items per page

Supplemental Content

Write to the Help Desk